TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07133308: A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period

Sponsor: Sun Pharmaceutical Industries, Inc. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 355 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,594,480

Rescue Site Savings

+$4,359,684

Unlock Full NCT07133308 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07133308 Rescue Dossier →